ImpediMed Statistics

Total Valuation

ImpediMed has a market cap or net worth of AUD 32.62 million. The enterprise value is 35.33 million.

Market Cap	32.62M
Enterprise Value	35.33M

Important Dates

The next estimated earnings date is Friday, April 24, 2026.

Earnings Date	Apr 24, 2026
Ex-Dividend Date	n/a

Share Statistics

ImpediMed has 2.04 billion shares outstanding. The number of shares has increased by 0.07% in one year.

Current Share Class	2.04B
Shares Outstanding	2.04B
Shares Change (YoY)	+0.07%
Shares Change (QoQ)	+0.94%
Owned by Insiders (%)	6.10%
Owned by Institutions (%)	14.22%
Float	1.81B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.29
PB Ratio	3.62
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.45
EV / Sales	2.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.29

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 2.39.

Current Ratio	3.74
Quick Ratio	3.30
Debt / Equity	2.39
Debt / EBITDA	n/a
Debt / FCF	-1.40
Interest Coverage	-7.34

Financial Efficiency

Return on equity (ROE) is -117.92% and return on invested capital (ROIC) is -43.59%.

Return on Equity (ROE)	-117.92%
Return on Assets (ROA)	-35.93%
Return on Invested Capital (ROIC)	-43.59%
Return on Capital Employed (ROCE)	-70.76%
Weighted Average Cost of Capital (WACC)	11.31%
Revenue Per Employee	184,831
Profits Per Employee	-316,532
Employee Count	77
Asset Turnover	0.37
Inventory Turnover	1.24

Taxes

In the past 12 months, ImpediMed has paid 29,000 in taxes.

Income Tax	29,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -61.90% in the last 52 weeks. The beta is 1.31, so ImpediMed's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	-61.90%
50-Day Moving Average	0.03
200-Day Moving Average	0.04
Relative Strength Index (RSI)	33.88
Average Volume (20 Days)	8,320,567

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ImpediMed had revenue of AUD 14.23 million and -24.37 million in losses. Loss per share was -0.01.

Revenue	14.23M
Gross Profit	12.26M
Operating Income	-22.29M
Pretax Income	-24.34M
Net Income	-24.37M
EBITDA	-22.16M
EBIT	-22.29M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 18.85 million in cash and 21.55 million in debt, giving a net cash position of -2.71 million or -0.00 per share.

Cash & Cash Equivalents	18.85M
Total Debt	21.55M
Net Cash	-2.71M
Net Cash Per Share	-0.00
Equity (Book Value)	9.02M
Book Value Per Share	0.00
Working Capital	18.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.39 million and capital expenditures -60,000, giving a free cash flow of -15.45 million.

Operating Cash Flow	-15.39M
Capital Expenditures	-60,000
Free Cash Flow	-15.45M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 86.14%, with operating and profit margins of -156.65% and -171.25%.

Gross Margin	86.14%
Operating Margin	-156.65%
Pretax Margin	-171.05%
Profit Margin	-171.25%
EBITDA Margin	-155.71%
EBIT Margin	-156.65%
FCF Margin	n/a

Dividends & Yields

ImpediMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.07%
Shareholder Yield	-0.07%
Earnings Yield	-74.72%
FCF Yield	-47.35%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImpediMed has an Altman Z-Score of -12.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.65
Piotroski F-Score	2